EGFL4 Inhibitors
EGFL4 inhibitors encompass a range of compounds that target various signaling pathways, ultimately leading to the reduced activity of EGFL4. Compounds like Erlotinib and Gefitinib target the EGFR tyrosine kinase, which is upstream of many signaling cascades, including those that may involve EGFL4. By inhibiting EGFR, the activation of downstream pathways like PI3K/AKT and MAPK/ERK, which can be crucial for EGFL4-mediated functions, is reduced. This leads to an overall decrease in the cellular processes that EGFL4 may regulate, such as proliferation, differentiation, or migration.
Other compounds, such as Rapamycin and LY294002, act on the mTOR and PI3K pathways, respectively. The inhibition of mTOR by Rapamycin can blunt the cell cycle progression and growth signals that EGFL4 is potentially involved in regulating. LY294002, by halting PI3K activity, leads to the dampening of the AKT signaling pathway, which is often a key mediator of survival and proliferation signals. These actions collectively contribute to the functional inhibition of EGFL4 by impairing the signaling environment it requires to exert its effects. Kinase inhibitors like Dasatinib and Imatinib can further extend the repertoire of EGFL4 inhibition by targeting Src family kinases and BCR-ABL tyrosine kinase, respectively, which may also intersect with EGFL4-related pathways, thus contributing to the inhibition of EGFL4's functional activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. By inhibiting EGFR, it can reduce the phosphorylation and activation of downstream signaling pathways such as PI3K/AKT that could be necessary for EGFL4-mediated signal transduction leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a key kinase in cell growth and proliferation. Since EGFL4 is associated with cell proliferation, inhibition of mTOR can indirectly suppress the functional effects of EGFL4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which attenuates the PI3K/AKT signaling pathway. If EGFL4 function is dependent on this pathway, its inhibition would lead to a decrease in EGFL4's functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which prevents the activation of the ERK/MAPK signaling pathway. As EGFL4 can be involved in MAPK signaling, its inhibition by U0126 can lead to a reduction in EGFL4's functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which can disrupt the JNK signaling pathway. If EGFL4 activity is modulated through JNK pathway, then this compound would impair EGFL4's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, potentially leading to decreased activation of processes that could be regulated by EGFL4, thereby inhibiting its functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, causing cellular stress and potentially inhibiting signaling pathways that EGFL4 might be involved in. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor with specificity towards RAF, VEGFR, and PDGFR. If EGFL4's function is related to these kinases, its inhibition would reduce EGFL4's functional activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits BCR-ABL tyrosine kinase, and could also affect related signaling pathways that may indirectly impact EGFL4 functional activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor, including Src family kinases. As Src kinases can participate in pathways involving EGFL4, dasatinib can lead to the inhibition of EGFL4's function. | ||||||